(Last updated : 2024-05-16 13:59:11)
  INAGAKI Ataru
   Department   Aoyama Gakuin University  Department of Education, College of Education, Psychology and Human Studies
   Position   Professor
■ Specialization and related fields
Clinical Psychiatry, Pharmacoepidemiology, Pharmacoeconomics 
■ Business career
1. 1992/05~1994/04 Keio University Hospital Neuropsychiatry Resident
2. 1993/05~2002/03 Yamanashi Prefectural Kita Hospital Psychiatry
3. 2002/04~2007/03 Keio University Department of Neuropsychiatry, School of Medicine Lecturer
4. 2006/04~2007/03 Keio University Hospital Department of Neuropsychiatry Division director for health insurance
5. 2007/04~2012/03 Keio University Graduate School of Health Management Project Associate Professor
Display all(12)
■ Belonging society
1. 1993/05~ The Japan Society of Psychiatry and Neurology Link
2. 2007/07~ International Society for Pharmacoeconomics and Outcomes Research Japan Chapter Link
3. 2007/07~2011/07 ∟ Secretary
4. 2007/11~ International Society for Pharmacoeconomics and Outcomes Research Link
5. 2021/12~ Japan University Health Administration Link
■ Official position and committee in Univ.
1. 2019/04/01~2021/03/31 Aoyama Gakuin University Associate Director, Healthcare Administration Center
2. 2021/04/01~2023/03/31 Aoyama Gakuin University Associate Director, Healthcare Administration Center
3. 2022/04/01~2023/03/31 Aoyama Gakuin University Director, Healthcare Administration Center
4. 2023/04/01~2025/03/31 Aoyama Gakuin University Associate Director, Healthcare Administration Center
5. 2023/04/01~2025/03/31 Aoyama Gakuin University Director, Healthcare Administration Center
Display all(6)
■ Book and thesis
1. Book A guide to master the Hamilton Depression Rating Scale: Commentary on the Hamilton Depression Rating Scale (HAMD) and guide to its usage.   (Collaboration) 2014/04
2. Article Budget impact analysis of long acting injection for schizophrenia in Japan J Med Econ 23(8),pp.848-855 (Collaboration) 2020
3. Article Treatment persistence between long-acting injectable versus orally administered aripiprazole among patients with schizophrenia in a real-world clinical setting in Japan Adv Ther 37(7),pp.3324-3336 (Collaboration) 2020
4. Article 101. 稲垣 中: . 32 (4): 354-361, 2018.  pp.354-361 (Single) 2018/04
5. Article Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method Int J Neuropsychopharmacol 18(5),pp.1-5 (Collaboration) 2015
Display all(6)